Nestle announced that it has decided to explore strategic options for Palforzia, the peanut allergy treatment, "following slower than expected adoption by patients and healthcare professionals." The review is expected to be completed in the first half of 2023. Going forward, Nestle Health Science "will sharpen its focus" on Consumer Care and Medical Nutrition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NSRGY: